March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Therapeutical Options In The Treatment Of Conjunctival Malignant Melanomas
Author Affiliations & Notes
  • Anita I. Mladenova
    Ophthalmology, Staedtisches Klinikum Dessau, Dessau, Germany
  • Michael H. Foerster
    Augenzentrum, DRK Kliniken Berlin Westend, Berlin, Germany
  • Lutz Moser
    Department of Radiation Oncology and Radiotherapy, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
  • Lothar Krause
    Ophthalmology, Staedtisches Klinikum Dessau, Dessau, Germany
  • Footnotes
    Commercial Relationships  Anita I. Mladenova, None; Michael H. Foerster, None; Lutz Moser, None; Lothar Krause, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 3989. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Anita I. Mladenova, Michael H. Foerster, Lutz Moser, Lothar Krause; Therapeutical Options In The Treatment Of Conjunctival Malignant Melanomas. Invest. Ophthalmol. Vis. Sci. 2012;53(14):3989.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Malignant melanomas of the conjunctiva represent a rare malignancy with an incidence of 0.2-0.8% in Western Europe. The high incidence of disease recurrence gives questions about the optimal adjuvant therapy.

Methods: : Retrospective study of 57 treated patients with histologically proved conjunctival melanomas in the period from 1992 to 2008. Mean age of the patients was 61 years (28-86 years). There were 30 men and 27 women. Mean follow up period was 83 months. All patients underwent excisional biopsy for further histological determination. In 15 cases the etiology was a melanosis, in 17 cases a nevus and in 25 patients was observed a de novo melanoma. Therapy included local excision (n=57), cryocoagulation (n=13), application of mitomycin C (n=14), brachytherapy with strontium or ruthenium plaques (n=30), proton beam irradiation (n=4), roentgen beam irradiation (n=12), enucleation (n=3) and exenteration (n=8).

Results: : 56% of patients (n=32) showed no sign of recurrence during the follow-up period, whereas in 21 % (n=12) a local recurrence was detected. In 22 % (n=13) a local recurrence or a new tumor with a different localisation occured. There were 17% (n=10) of patients with metastatic manifestations.

Conclusions: : Adjuvant therapy is necessary to complete the initially performed excisional surgery in combination with cryocoagulation to minimize the risk of recurrence.

Keywords: conjunctiva • melanoma 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×